Stem Cell Modeling of Core Binding Factor Acute Myeloid Leukemia

Stem Cells International
Federico Mosna, Michele Gottardi

Abstract

Even though clonally originated from a single cell, acute leukemia loses its homogeneity soon and presents at clinical diagnosis as a hierarchy of cells endowed with different functions, of which only a minority possesses the ability to recapitulate the disease. Due to their analogy to hematopoietic stem cells, these cells have been named "leukemia stem cells," and are thought to be chiefly responsible for disease relapse and ultimate survival after chemotherapy. Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) is cytogenetically characterized by either the t(8;21) or the inv(16)/t(16;16) chromosomal abnormalities, which, although being pathognomonic, are not sufficient per se to induce overt leukemia but rather determine a preclinical phase of disease when preleukemic subclones compete until the acquisition of clonal dominance by one of them. In this review we summarize the concepts regarding the application of the "leukemia stem cell" theory to the development of CBF AML; we will analyze the studies investigating the leukemogenetic role of t(8;21) and inv(16)/t(16;16), the proposed theories of its clonal evolution, and the role played by the hematopoietic niches in preserving the disease. Finally, we will discuss the cl...Continue Reading

References

Oct 1, 1976·Science·P C Nowell
Aug 20, 1987·The New England Journal of Medicine·P J FialkowR Veith
May 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K MrózekC D Bloomfield
Jul 3, 2002·Nature Reviews. Cancer·Nancy A Speck, D Gary Gilliland
Aug 15, 2002·Blood·D Gary Gilliland, James D Griffin
Aug 27, 2002·Annual Review of Genomics and Human Genetics·Louise M Kelly, D Gary Gilliland
Sep 3, 2003·Nature Reviews. Cancer·Mel F Greaves, Joe Wiemels
Oct 24, 2003·Nature·L M CalviD T Scadden
Mar 10, 2004·Proceedings of the National Academy of Sciences of the United States of America·Claudia D BaldusAlbert de la Chapelle
Mar 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John C ByrdClara D Bloomfield
Sep 21, 2004·Oncogene·Craig T Jordan, Monica L Guzman
Jan 25, 2005·Nature Immunology·Andrew W DuncanTannishtha Reya
Jun 2, 2005·The Journal of Experimental Medicine·Sebastian StierDavid T Scadden
Aug 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciClara D Bloomfield
Nov 11, 2005·Leukemia·G PereaUNKNOWN Grupo Cooperativo para el Estudio y Tratamiento de las Leucemias Agudas y Miel
Dec 7, 2005·The Journal of Experimental Medicine·Emmanuelle PasseguéIrving L Weissman
Feb 24, 2006·European Journal of Haematology·Nancy Van Overstraeten-SchlögelAndré Gothot
May 4, 2006·The Journal of Clinical Investigation·Tong Yin, Linheng Li
Jul 25, 2006·Nature·Andrei V KrivtsovScott A Armstrong
Aug 31, 2006·British Journal of Haematology·Frederick R AppelbaumElihu H Estey
Sep 26, 2006·Nature Medicine·Daniela S KrauseRichard A Van Etten
Sep 26, 2006·Nature Medicine·Liqing JinJohn E Dick
Nov 17, 2006·Nature Reviews. Cancer·Lauren M F MerloCarlo C Maley
Mar 22, 2007·Proceedings of the National Academy of Sciences of the United States of America·Kalindi ParmarJulian D Down
Mar 24, 2007·The Journal of Clinical Investigation·Shotaro IwamotoDario Campana
Oct 24, 2007·Nature Biotechnology·Fumihiko IshikawaLeonard D Shultz
Aug 12, 2008·Seminars in Oncology·Peter Paschka
Oct 23, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Hideki NakasoneKensuke Usuki
Dec 5, 2008·Nature·Elsa QuintanaSean J Morrison
Sep 25, 2009·The New England Journal of Medicine·Bob LöwenbergUNKNOWN Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group
Sep 25, 2009·The New England Journal of Medicine·Hugo F FernandezMartin S Tallman
Nov 26, 2009·Biochimica Et Biophysica Acta·Andriy Marusyk, Kornelia Polyak
Dec 23, 2009·Seminars in Cancer Biology·Steven W Lane, D Gary Gilliland

❮ Previous
Next ❯

Citations

Jun 8, 2017·Journal of Clinical Medicine·Federico MosnaMichele Gottardi
Sep 22, 2020·Minerva medica·MIchele GottardiClaudio Cerchione

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01238211
NCT00850382

Software Mentioned

Plerixafor

Related Concepts

Related Feeds

Adult Stem Cells

Adult stem cells reside in unique niches that provide vital cues for their survival, self-renewal, and differentiation. They hold great promise for use in tissue repair and regeneration as a novel therapeutic strategies. Here is the latest research.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

Adhesion Molecules in Health and Disease

Cell adhesion molecules are a subset of cell adhesion proteins located on the cell surface involved in binding with other cells or with the extracellular matrix in the process called cell adhesion. In essence, cell adhesion molecules help cells stick to each other and to their surroundings. Cell adhesion is a crucial component in maintaining tissue structure and function. Discover the latest research on adhesion molecule and their role in health and disease here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.